Main Research and Development Centers
Each of our R&D centers specializes in a different area of scientific exploration. We have several major campuses located throughout the U.S. and U.K.
Andover, Massachusetts
A 70-acre site that combines state-of-the-art R&D facilities with flexible, multi-product manufacturing capabilities.
Cambridge, Massachusetts
Located in Kendall Square, our Cambridge site interlaces Pfizer’s R&D capability with the densest biomedical community in the world.
Groton, Connecticut
As the company’s largest R&D facility, Groton is involved in the development of nearly every Pfizer medicine and vaccine.
La Jolla, California
With more than 500,000 square feet of state-of-the-art facilities, this is where our scientists discover and develop cutting-edge cancer therapies using advanced laboratories and equipment.
Pearl River, New York
The primary location for our company’s global Vaccine Research and Development work.
Sandwich, UK
Home of the Pharmaceutical Sciences and Global Regulatory Affairs groups.
St. Louis, MO
A 300,000 sq. ft. facility producing innovative emergency care products that serve unique needs during severe medical crises.

Clinical Trials
Learn more about the process of joining a clinical trial and find a trial near you.
Go to Pfizer Clinical Trials Site DetailsRelated Articles
Podcast Highlights Pfizer Foundation’s Mission to Improve Breast Cancer Outcomes
For over 75 years, the Pfizer Foundation, a charitable organization, has worked toward the mission of helping build healthier communities around the world.
Science & Innovation
Not Quite Out of the Woods: Risk for Lyme Disease Prevails in Suburban Environments
Encounters with infected ticks that can cause Lyme disease can happen doing routine activities around the yard, and common outdoor activities in your everyday life can put you at heightened risk for tick bites and, in turn, contracting Lyme disease.
What is Non-Muscle Invasive Bladder Cancer?
According to recent research, bladder cancer is the 12th most common type of cancer worldwide. Of these cases, doctors stage (referring to the process of how far the cancer has progressed) about 75% as non-muscle invasive bladder cancer (NMIBC).










